| 5762 |
Centers for Disease Control and Prevention |
Html |
en |
Morpholine - NIOSH Pocket Guide to Chemical Hazards |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 8135 |
Centers for Disease Control and Prevention |
Html |
en |
Preconception Care, Show Your Love Campaign - Images, Physical Activity |
null |
| Save target | 0.868127 |
| right click | 0.950907 |
|
|
CLICK HERE |
| 8861 |
Centers for Disease Control and Prevention |
Html |
en |
Update: Severe Respiratory Illness Associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - Worldwide, 2012-2013 |
CDC continues to work in consultation with the World Health Organization (WHO) and other partners to better understand the public health risk posed by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), formerly known as novel coronavirus, which was first reported to cause human infection in September 2012 (1–4). The continued reporting of new cases indicates that there is an ongoing risk for transmission to humans in the area of the Arabian Peninsula. New reports of cases outside the region raise concerns about importation to other geographic areas. |
| mild respiratory illnesses | 0.336654 |
| CDC | 0.298428 |
| stool specimens | 0.232744 |
| east respiratory syndrome | 0.862637 |
| CDC Emergency Operations | 0.248077 |
| respiratory tract specimens | 0.458054 |
| rRT-PCR assay | 0.226509 |
| novel coronavirus | 0.364392 |
| public health risk | 0.256898 |
| human-to-human transmission | 0.235158 |
| bronchial wash | 0.235102 |
| World Health Organization | 0.464911 |
| patients | 0.242219 |
| syndrome coronavirus infections | 0.272819 |
| severe respiratory disease | 0.448345 |
| illness onset | 0.240515 |
| Arabian Peninsula | 0.521915 |
| probable case | 0.234334 |
| respiratory illness | 0.531608 |
| United States | 0.226309 |
| mild respiratory illness | 0.402984 |
| infection control | 0.312646 |
| health-care personnel | 0.236944 |
| Saudi Arabia | 0.511118 |
| M. Novel coronavirus | 0.272612 |
|
| respiratory symptoms | 0.358412 |
| severe acute respiratory | 0.372243 |
| infection control precautions | 0.235281 |
| incubation period | 0.24003 |
| laboratory-confirmed cases | 0.257012 |
| eastern Saudi Arabia | 0.348198 |
| local health departments | 0.327905 |
| lower respiratory tract | 0.660073 |
| public health | 0.305069 |
| website (http://www.cdc.gov/coronavirus/mers/case-def.html). | 0.228034 |
| acute respiratory illness | 0.526418 |
| respiratory tract specimen | 0.325979 |
| Middle East Respiratory | 0.772445 |
| cases | 0.401287 |
| United Arab Emirates | 0.429725 |
| MERS-CoV infection | 0.3544 |
| clinical respiratory | 0.274808 |
| local public health | 0.23343 |
| respiratory syndrome coronavirus | 0.91219 |
| patient-to-patient nosocomial transmission | 0.243653 |
| close contacts | 0.366844 |
| infection control procedures | 0.262452 |
| bronchoalveolar lavage | 0.311222 |
| Coronavirus Study Group | 0.270784 |
|
CLICK HERE |
| 8937 |
Centers for Disease Control and Prevention |
Html |
en |
Vaccine Information Statement: Meningococcal - Vaccines - CDC |
Meningococcal ACWY (MenACWY and MPSV4) Vaccine Information Statement |
| meningococcal disease outbreak | 0.630598 |
| health care provider | 0.71061 |
| Page | 0.500266 |
| National Vaccine Injury | 0.589594 |
| skin grafts | 0.461629 |
| severe allergic reaction | 0.788738 |
| additional doses | 0.490304 |
| College freshmen | 0.459565 |
| MenACWY vaccine | 0.573861 |
| meningococcal ACWY vaccine | 0.806677 |
| severe allergy | 0.474904 |
| Vaccine Adverse Event | 0.591278 |
| VAERS website | 0.46358 |
| nervous system problems | 0.45979 |
| life-threatening allergic reaction | 0.526361 |
| meningococcal disease | 0.961696 |
| booster dose | 0.464292 |
| young adults | 0.465486 |
| previous dose | 0.463867 |
| single dose | 0.464453 |
| U.S. military recruits | 0.506201 |
| persistent complement component | 0.505904 |
| Drug Administration | 0.459012 |
| N. meningitidis | 0.530702 |
| certain groups | 0.462492 |
|
| certain people | 0.48818 |
| meningococcal vaccines | 0.585695 |
| lengthy contact | 0.461896 |
| meningococcal conjugate vaccine | 0.737923 |
| Meningococcal ACWY vaccines | 0.636693 |
| state health department | 0.498133 |
| mild illness | 0.459019 |
| close contact | 0.460951 |
| spinal cord | 0.46052 |
| vaccine package insert | 0.596395 |
| Current Edition Date | 0.520539 |
| booster doses | 0.485107 |
| vaccine safety site | 0.595797 |
| severe pain | 0.470414 |
| people | 0.588597 |
| preferred vaccine | 0.564095 |
| certain vaccines | 0.46355 |
| routine vaccination | 0.468286 |
| certain medical conditions | 0.612738 |
| Neisseria meningitidis. | 0.468269 |
| vaccine | 0.832654 |
| different meningococcal vaccine | 0.7393 |
| severe scars | 0.482096 |
| meningococcal polysaccharide vaccine | 0.739322 |
|
CLICK HERE |
| 10529 |
Centers for Disease Control and Prevention |
Html |
en |
Email Updates: January 3, 2012'Clinicians Outreach and Communication Activity (COCA) |
CDC Clinician Outreach and Communication Activity (COCA). Providing clinicians the most current and reliable information on emerging public health threats, such as pandemics, natural disasters, and bioterrorism. |
| CDC | 0.932809 |
| Local leaders | 0.418806 |
| great time | 0.403343 |
| Emergency Preparedness | 0.446638 |
| recovery measures | 0.410324 |
| CDC website | 0.623382 |
| interactive sessions | 0.409322 |
| Weekly Flu View | 0.509053 |
| risk communication principles | 0.504797 |
| EID Home Page | 0.503293 |
| multi-state outbreaks | 0.424745 |
| non-Federal organizations | 0.403658 |
| TB prevention | 0.451189 |
| Preparedness Summit pre-session | 0.54134 |
| 122-Cities Mortality Reporting | 0.480095 |
| best partnership-communications practices | 0.500868 |
| winter emergencies | 0.410737 |
| weather-related health problems | 0.536239 |
| extremely cold weather | 0.49242 |
| action plan | 0.411635 |
| extreme cold-weather conditions | 0.491249 |
| Carbon Monoxide | 0.404685 |
| Environmental Public Health | 0.553456 |
| Winter Sports | 0.417012 |
| foodborne illness cases | 0.466984 |
|
| Winter Weather | 0.418405 |
| New Media Outreach | 0.501378 |
| flu vaccine | 0.416778 |
| COCA Email Update | 0.512279 |
| Infectious disease outbreaks | 0.505915 |
| MMWR weekly reports | 0.485369 |
| TB program staff | 0.530269 |
| Building Support | 0.410087 |
| health care workers | 0.893107 |
| CDC Current Outbreak | 0.688043 |
| public cooperation | 0.425031 |
| Communications Planning | 0.410218 |
| Specific Hazards preparedness | 0.536828 |
| Dec | 0.409613 |
| Health Partners Outreach | 0.548055 |
| preventive action | 0.405963 |
| food safety systems | 0.471899 |
| in-person training centers | 0.493941 |
| Tracking Network | 0.40624 |
| Public Health Preparedness | 0.703939 |
| best defense | 0.405198 |
| Health Preparedness Summit | 0.698798 |
| warmer weather | 0.403095 |
| news conference | 0.415831 |
|
CLICK HERE |
| 12405 |
Centers for Disease Control and Prevention |
Image |
null |
Motor Vehicle Prioritizing Interventions and Cost Calculator for States (1175W x 347H) |
null |
|
|
CLICK HERE |
| 12473 |
Centers for Disease Control and Prevention |
Video |
en |
June 2013 ACIP Meeting -- Pertussis Vaccines |
Introduction by Dr. M Sawyer. Pertussis in the United States and Tdap vaccine effectiveness by Dr. A Acosta. Tdap revaccination: safety and immunogenicity by Dr. J Liang. Decision and cost effectiveness analysis: a second dose of Tdap by Dr. M. Messonnier, Dr. H Kamiya. Work group conclusions on a second dose of Tdap by Dr. J Liang. Maternal Tdap and cocooning: experiences from Australia and the United Kingdom by Dr. P McIntyre, Dr. D Salisbury.
Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html
This video can also be viewed at: http://streaming.cdc.gov/vod.php?id=8a1f7d5638cd206be3b576b1969e0f0520130730141810953 |
| Pertussis Vaccines | 0.926187 |
|
|
CLICK HERE |
| 12542 |
Centers for Disease Control and Prevention |
Video |
en |
CDC: Erica's Story, Let's Stop HIV Together |
In this digital story, Erica talks about living with HIV as a transgender woman and reassures others that it is okay to be open, discuss your HIV status, and live your best life. The more educated people are about HIV, the better they are at protecting themselves and protecting others.
Let's Stop HIV Together is a national HIV awareness and anti-stigma campaign produced by the Centers for Disease Control and Prevention (CDC). It features stories of individuals living with HIV and the people who support them. Join the conversation on Facebook at www.facebook.com/ActAgainstAIDS.
Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html
This video can also be viewed at
http://streaming.cdc.gov/vod.php?id=c4c3da593e1399fd4e132b1b2dda304620131122093611390 |
| CDC | 0.701155 |
| Erica | 0.734362 |
|
|
CLICK HERE |
| 14433 |
Centers for Disease Control and Prevention |
Html |
en |
Brucellosis | Risk of Exposure |
Information on the risk of exposure to brucellosis infection. |
| settings | 0.22956 |
| Wildlife Services | 0.564475 |
| unpasteurized milk | 0.807431 |
| occupations | 0.284258 |
| Photo courtesy | 0.643975 |
| mothers | 0.237064 |
|
| exposure | 0.221952 |
| United States Department | 0.971575 |
| brucellosis | 0.946628 |
| Plant Health Inspection | 0.962075 |
| dairy products | 0.627545 |
| increased risk | 0.5961 |
|
CLICK HERE |
| 15913 |
Centers for Disease Control and Prevention |
Html |
null |
Medication Adherence | Million Hearts |
Medication Adherence |
|
|
CLICK HERE |